ClinicalTrials.gg
RecruitingNCT06087783PRODIGY-1Updated Nov 4, 2026

PROtein, Leucine and Vitamin D Supplementation In Patients With GYnecologic Cancer Receiving Platinum-based Chemotherapy

An interventional study of Experimental product - Fortifit® Powder and Standard of care in Gynecologic Cancer, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Recruiting at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.
Updated Nov 4, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Open clinical trial addressing the effect of a nutritional support based on whey proteins, leucine and vitamin D on muscle mass and multiple anticancer treatment-related endpoints in patients with gynecologic cancer receiving first-line platinum-based chemotherapy (adjuvant or curative). A comparison to matched historical controls will be performed to address potential evidence of efficacy to be investigated in a subsequent randomized trial.

02

Conditions studied

  • Gynecologic Cancer
03

In context

Lead sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia is the lead sponsor of 258 studies on the registry; 115 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of gynecologic cancer (ovarian, uterine, cervical);
  • indication for a chemotherapy (adjuvant or curative) with a platinum-based regimen to be used by investigator's choice within the framework of good clinical practice and in agreement with current Italian Association of Medical Oncology guidelines;
  • (ECOG) performance status ≤2;
  • signed .

Exclusion criteria

Exclusion Criteria:

  • age \<18 years
  • performance status >2
  • indication to or ongoing artificial nutrition support
  • known kidney failure (previous \<30 ml/min);
  • known liver failure (Child B or C)
  • endocrine disorders associated with disorders of calcium metabolism (excluding osteoporosis)
  • decompensated diabetes
  • indications related to the study product: more than 10 µg (400 IU) of daily Vitamin D intake from medical sources More than 500 mg of daily calcium intake from medical sources; adherence to a high energy or high protein diet up or use of protein containing or amino acid containing nutritional supplements up to three months before starting the study.
  • known allergy to milk, milk products or other components of the proposed interventions
  • inclusion in other nutritional intervention trials
  • patients refusal
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Muscle-targeted nutritional support

    Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.

    Dietary Supplement: Experimental product - Fortifit® Powder

  • Other
    Standard of care

    Control group receiving no nutritional intervention or on-demand non muscle-targeted nutritional intervention such as nutritional counseling with or without oral nutritional supplement

    Other: Standard of care

Interventions

  • Dietary supplementExperimental product - Fortifit® Powder

    Two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.

    Also known as: Muscle-targeted nutritional support

  • OtherStandard of care

    Control group receiving no nutritional intervention or on-demand non muscle-targeted intervention such as nutritional counseling with or without oral nutritional supplement

06

What researchers measure

Primary outcomes

  1. Change in muscle mass area

    Change in muscle mass at the end of first-line platinum-based chemotherapy (adjuvant or curative) evaluated with computed tomography scan at the level of the third lumbar vertebra

    Time frame: 18 weeks

Secondary outcomes

  1. Skeletal muscle mass

    Change in skeletal muscle mass during the study evaluated with bioimpedance vectorial analysis

    Time frame: 18 weeks

  2. Body weight

    Change in body weight during the study (assessed at each chemotherapy cycle)

    Time frame: 18 weeks

  3. Protein-calorie intake

    Change in protein-calorie intake during the study (assessed at each chemotherapy cycle)

    Time frame: 18 weeks

  4. Handgrip strength

    Change in handgrip strength

    Time frame: 18 weeks

  5. Treatment-related moderate-severe adverse events as assessed by Common Terminology Criteria for Adverse Events [CTCAE v5.0]

    Difference in the incidence of grade \>=3 toxicity, according to CTCAE v5.0. Toxicity is graded on 0-5 ordinal scale where a higher score means a worse outcome.

    Time frame: 18 weeks

  6. Adherence to treatment schedule

    Difference in the proportion of patients completing the treatment schedule as planned

    Time frame: 18 weeks

  7. Total dose of chemotherapy administered

    To be calculated as the percentage of chemotherapy dose administered with respect to the treatment plan

    Time frame: 18 weeks

  8. Patients requiring unplanned hospitalization

    The rate of patients requiring unplanned hospitalization (one or more) during the study will be calculated

    Time frame: 18 weeks

  9. Tolerance to nutritional support

    Occurrence of events of gastrointestinal intolerance

    Time frame: 18 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2024 (actual). Primary completion is estimated for Mar 2027, 32 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Nov 2026 → Mar 2027 and completion Nov 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2023
First posted
Oct 18, 2023
StartActual
Jul 8, 2024
Primary completionEst.
Mar 30, 2027was Nov 2026
CompletionEst.
Mar 30, 2027was Nov 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • IRCCS San Matteo · Pavia, Italy
Show 1 removed
  • IRCCS San Matteo · Pavia, Italy
Nov 4, 2026
Primary completion
Nov 30, 2026→Mar 30, 2027
Nov 4, 2026
Study completion
Nov 30, 2026→Mar 30, 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    1 site added, 1 site removed
    Show site
    • IRCCS San Matteo · Pavia, Italy
    Show 1 removed
    • IRCCS San Matteo · Pavia, Italy
    Primary completion Nov 30, 2026→Mar 30, 2027
    Study completion Nov 30, 2026→Mar 30, 2027
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06087783
Responsible party
Emanuele Cereda (Principal Investigator, Fondazione IRCCS Policlinico San Matteo di Pavia) — Principal investigator
First posted
Oct 18, 2023
Start date
Jul 8, 2024
Primary completion
Mar 30, 2027 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Emanuele Cereda, MD, PhD
Contact
e.cereda@smatteo.pv.it
+390382501615
Riccardo Caccialanza, MD
Contact
r.caccialanza@smatteo.pv.it
+390382501615
Emanuele Cereda, MD, PhD
principal investigator · Fondazione IRCCS Policlinico San Matteo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion